-
Chinese Patient Study: Misfortune and Fortune!
Time of Update: 2022-08-12
In this retrospective cohort study, 468 cancer patients who received immunotherapy at a tertiary referral center in Taiwan were finally included and sought to determine the true incidence of skin immune-related adverse events and their association with survival .
-
Cisplatin, carboplatin, oxaliplatin... What is the difference between the five platinum drugs?
Time of Update: 2022-08-12
Platinum drugs are non-specific drugs in the cell cycle, which mainly inhibit the transcription and replication of DNA, thereby promoting tumor cell apoptosis and exerting anti-tumor effects . Platin
-
Eur Radiol: You must not underestimate this CT sign of lung cancer patients!
Time of Update: 2022-08-12
. A study published in the European Radiology journal evaluated smokers with normal lung capacity who underwent lobectomy for lung cancer and further compared the association of emphysema on CT with PAL and respiratory complications .
-
Nature sub-journal: Screening of clinical drug candidates through organoids derived from solid tumor cancer patients
Time of Update: 2022-08-12
. On April 25, 2022, researchers from CrownBio, Merus, and the Barcelona Institute of Science and Technology jointly published a paper entitled: Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR in Nature Cancer, a sub-journal of Nature × Research paper on LGR5 bispecific antibody with efficacy in epithelial tumors .
-
A major breakthrough in Helicobacter pylori research!
Time of Update: 2022-08-12
. Further mouse experiments confirmed that Hp infection promoted the expression of FGFR4 in gastric cancer cells .
. Further mouse experiments confirmed that Hp infection promoted the expression of FGFR4 in gastric cancer cells .
-
Clin Cancer Res: Efficacy of enzalutamide combined with samotolisib in the treatment of metastatic drug-resistant prostate cancer
Time of Update: 2022-08-12
. In conclusion, samotolisib/enzalutamide significantly improved progression-free survival in patients with metastatic-resistant prostate cancer that had progressed on abiraterone, was well tolerated , and was free of androgen receptor splice variant 7.
-
Lancet Oncol: Treatment of Relapsed/Refractory Malignant Pleural Mesothelioma with EZH2 Inhibitor Tzemetostat
Time of Update: 2022-08-12
9 weeks, the disease control rate in patients with BAP1 inactivation at week 12 was 54%After a median follow-up of 35.
9 weeks, the disease control rate in patients with BAP1 inactivation at week 12 was 54%After a median follow-up of 35.
-
ASCO: Phase 2 study of continuous talazopanib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer
Time of Update: 2022-08-10
TALA plus TMZ treatmentThe primary outcome measure was objective response rate (ORR) based on RECIST 1.
TALA plus TMZ treatmentThe primary outcome measure was objective response rate (ORR) based on RECIST 1.
TALA plus TMZ treatmentThe primary outcome measure was objective response rate (ORR) based on RECIST 1.
-
Yttrium [90Y] microsphere injection was put into use, and the treatment of liver tumors entered the "Yttrium Era"
Time of Update: 2022-08-10
On May 7, Grand Pharmaceuticals (China) Co. , Ltd. announced that its global innovative product SIR-Spheres® Yttrium [90Y] Microsphere Injection for the treatment of hepatic malignancies was officiall
-
The payment or nearly 1.4 billion US dollars, Merck authorized the Columbotai macromolecular tumor project to go overseas!
Time of Update: 2022-08-10
Photo of Rong Media Center, Wenjiang District, Chengdu The staff of the Medicinal Chemistry Department of Sichuan Kelun Botai Biomedical Co.
Photo of Rong Media Center, Wenjiang District, Chengdu The staff of the Medicinal Chemistry Department of Sichuan Kelun Botai Biomedical Co.
-
The overall response rate was 96%, and Mustang Bio announced the latest clinical data on CD20 CAR-T therapy
Time of Update: 2022-06-02
April 27, 2022/eMedClub News/--On April 25, 2022, Mustang Bio (Mustang Bio) announced the interim data of the ongoing Phase 1/2 clinical trial of MB-106, which is An autologous CAR-T cell therapy targeting CD20, co-developed by Mustang and Fred Hutchinson Cancer Center (Fred Hutch), for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic Lymphocytic leukemia (CLL) .
-
Progesterone use may be linked to increased risk of thyroid cancer, study finds
Time of Update: 2022-06-01
A recent retrospective study of more than 140,000 infertile women in Denmark found that women who used progesterone had an approximately 60% increased risk of developing thyroid cancer compared to women who had never used progesterone, but the overall risk was very high.
-
Ying Tianlei/Wu Yanling/Ding Lin of Fudan University jointly develop a new generation of fully human nanobody conjugated drugs for solid tumors
Time of Update: 2022-06-01
Recently, the team of Ying Tianlei and Wu Yanling from the School of Basic Medicine of Fudan University and the team of Ding Lin from the School of Life Sciences jointly published the research results of A highly stable human single-domain antibody-drug conjugateexhibits superior penetration and treatment of solid tumors in the Molecular Therapy journal.
-
Peptide receptor radionuclide therapy for refractory midgut neuroendocrine tumors
Time of Update: 2022-06-01
PRRT has been approved for the treatment of well-differentiated midgut neuroendocrine tumors that have progressed after somatostatin analog (SSA) therapy based on the prolongation of progression-free survival (PFS) observed in the NETTER-1 trial (NEJM JW Oncol Hematol Mar 2017 and N Engl J Med 2017;376:125) .
-
The double combo makes cancer cells unable to escape, and the "Science" sub-journal is expected to bring new anti-cancer treatments
Time of Update: 2022-06-01
▎WuXi AppTec Content Team Editor Recently, a study in Science-Translational Medicine demonstrated clinical results of a new combination therapy, using both immunotherapy and targeted drugs to effectively prolong survival in patients with advanced kidney cancer , reduce the rate of cancer recurrence .
-
J Clin Oncol: Women with breast cancer receiving anticancer therapy are associated with increased risk of cardiovascular disease and mortality
Time of Update: 2022-06-01
A prospective cohort study from J Clin Oncol examined whether there were significant differences in CVD and mortality risk among women with BC who received anticancer therapy compared with women who did not receive breast cancer therapy.
-
Article Summary: Genetic Testing in Kidney Cancer
Time of Update: 2022-06-01
Although molecular typing based on genetic testing has not been used as a reference for mRCC treatment in domestic and foreign guidelines and consensuses, in recent domestic and foreign studies, gene mutations have a certain role in the clinical diagnosis, efficacy evaluation, and prognosis prediction of renal cancer.
-
CCO experts talk about I field perspective, cutting-edge style, Professor Zhang Qingyuan shares the latest progress in lymphoma treatment
Time of Update: 2022-06-01
In recent years, the development of new drugs, the rise of the combination drug model, and the popularization of medical insurance policies have greatly promoted the progress in the field of lymphoma.
-
What are the individualized treatments for HER2-mutant non-small cell lung cancer?
Time of Update: 2022-06-01
A phase II clinical study showed that the objective response rate of 18 patients with HER2-mutated non-small cell lung cancer treated with TDM-1 was 44%, and the median progression-free survival was 5 months (Figure 3) [5] .
-
The data of Nkarta's two CAR-NKs are amazing, and the global market of CAR-NK is continuing to update!
Time of Update: 2022-06-01
▲ Image source: Senti Bio announced the preclinical data of its CAR-NK cell therapy in the treatment of solid tumors at the 2022 American Association for Cancer Research (AACR) annual meeting .
